Loading...
Loading...
CRDL| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 58.2K |
| Gross Profit | -58.2K |
| Operating Expense | 7,786.1K |
| Operating I/L | -7,937.0K |
| Other Income/Expense | 696.8K |
| Interest Income | 545.9K |
| Pretax | -7,089.3K |
| Income Tax Expense | -696.8K |
| Net Income/Loss | -7,089.3K |
Cardiol Therapeutics Inc. is a clinical-stage life sciences company specializing in anti-fibrotic and anti-inflammatory therapies for cardiovascular disease. Their lead product, CardiolRx, is undergoing Phase II/III trials for cardioprotective therapy in COVID-19 patients and acute myocarditis. Additionally, the company is developing a subcutaneous formulation of CardiolRx for heart-related fibrosis and inflammation, targeting heart failure progression.
